Cancer Research Grants  Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zeng, H.
Right arrow Articles by Kruh, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zeng, H.
Right arrow Articles by Kruh, G. D.
[Cancer Research 61, 7225-7232, October 1, 2001]
© 2001 American Association for Cancer Research


Experimental Therapeutics

Transport of Methotrexate (MTX) and Folates by Multidrug Resistance Protein (MRP) 3 and MRP1

Effect of Polyglutamylation on MTX Transport1

Hao Zeng2, Zhe-Sheng Chen3, Martin G. Belinsky, Philip A. Rea and Gary D. Kruh4

Medical Science Division, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [H. Z., Z-S. C., M. G. B., G. D. K.], and Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 [P. A. R.]

We have recently determined that human multidrug resistance protein (MRP) 3, which confers resistance to certain natural product agents and methotrexate (MTX), is competent in the MgATP-energized transport of MTX and the monoanionic bile constituent glycocholate as well as several glutathione and glucuronate conjugates. Of these capabilities, the facility of MRP3 in conferring resistance to and mediating the transport of MTX is of particular interest because it raises the possibility that this pump is a component of the previously described cellular efflux system for this antimetabolite. However, if this is to be the case, a critical property of cellular MTX efflux that must be addressed is its ability to mediate the export of MTX but not that of its intracellular polyglutamylated derivatives. Here we examine the role of MRP3 in these and related processes by determining the selectivity of this transporter for MTX, MTX polyglutamates, and physiological folates. In so doing, we show that MRP3 is not only active in the transport of MTX but is also active in the transport the physiological folates folic acid (FA) and N5-formyltetrahydrofolic acid (leucovorin) and that polyglutamylation of MTX abolishes transport. Both FA and leucovorin are subject to high-capacity (Vmax(FA), 1.71 ± 0.05 nmol/mg/min; Vmax(leucovorin), 3.63 ± 1.20 nmol/mg/min), low-affinity (Km(FA), 1.96 ± 0.13 mM; Km(leucovorin), 1.74 ± 0.65 mM) transport by MRP3. Addition of a single glutamyl residue to MTX is sufficient to diminish transport by >95%. We also show that polyglutamylation similarly affects the capacity of MRP1 to transport MTX and that physiological folates are also subject to MgATP-stimulated transport by MRP1. On the basis of the capacity to transport MTX but not MTX-Glu2, it is concluded that MRP3 and MRP1 represent components of the previously described cellular efflux system for MTX. The capacity of MRP3 to transport folates indicates that it may reduce intracellular levels of these compounds and thereby indirectly influence antifolate cytotoxicity, and it also implies that this pump may play a role in the response to chemotherapeutic regimens in which leucovorin is a component.




This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
S. Dahlstrom, M. I. Veiga, A. Martensson, A. Bjorkman, and J. P. Gil
Polymorphism in PfMRP1 (Plasmodium falciparum Multidrug Resistance Protein 1) Amino Acid 1466 Associated with Resistance to Sulfadoxine-Pyrimethamine Treatment
Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2553 - 2556.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Raichaudhuri, M. Peng, V. Naponelli, S. Chen, R. Sanchez-Fernandez, H. Gu, J. F. Gregory III, A. D. Hanson, and P. A. Rea
Plant Vacuolar ATP-binding Cassette Transporters That Translocate Folates and Antifolates in Vitro and Contribute to Antifolate Tolerance in Vivo
J. Biol. Chem., March 27, 2009; 284(13): 8449 - 8460.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Kitamura, M. Hirouchi, H. Kusuhara, J. D. Schuetz, and Y. Sugiyama
Increasing Systemic Exposure of Methotrexate by Active Efflux Mediated by Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3)
J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 465 - 473.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Ifergan, G. Jansen, and Y. G. Assaraf
The Reduced Folate Carrier (RFC) Is Cytotoxic to Cells under Conditions of Severe Folate Deprivation: RFC AS A DOUBLE EDGED SWORD IN FOLATE HOMEOSTASIS
J. Biol. Chem., July 25, 2008; 283(30): 20687 - 20695.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Matsushima, K. Maeda, H. Hayashi, Y. Debori, A. H. Schinkel, J. D. Schuetz, H. Kusuhara, and Y. Sugiyama
Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine
Mol. Pharmacol., May 1, 2008; 73(5): 1474 - 1483.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
S. L. Hider, I. N. Bruce, and W. Thomson
The pharmacogenetics of methotrexate
Rheumatology, October 1, 2007; 46(10): 1520 - 1524.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
S L Hider, A Owen, R Hartkoorn, S Khoo, D Back, A J Silman, and I N Bruce
Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug
Ann Rheum Dis, October 1, 2006; 65(10): 1390 - 1393.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
R. G. Deeley, C. Westlake, and S. P. C. Cole
Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins.
Physiol Rev, July 1, 2006; 86(3): 849 - 899.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. D. Cole, R. A. Drachtman, A. K. Smith, S. Cate, R. A. Larson, D. S. Hawkins, J. Holcenberg, K. Kelly, and B. A. Kamen
Phase II Trial of Oral Aminopterin for Adults and Children with Refractory Acute Leukemia
Clin. Cancer Res., November 15, 2005; 11(22): 8089 - 8096.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Bedhomme, M. Hoffmann, E. A. McCarthy, B. Gambonnet, R. G. Moran, F. Rebeille, and S. Ravanel
Folate Metabolism in Plants: AN ARABIDOPSIS HOMOLOG OF THE MAMMALIAN MITOCHONDRIAL FOLATE TRANSPORTER MEDIATES FOLATE IMPORT INTO CHLOROPLASTS
J. Biol. Chem., October 14, 2005; 280(41): 34823 - 34831.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Y. Liu, H. Peng, and J.-T. Zhang
Expression Profiling of ABC Transporters in a Drug-Resistant Breast Cancer Cell Line Using AmpArray
Mol. Pharmacol., August 1, 2005; 68(2): 430 - 438.
[Abstract] [Full Text] [PDF]


Home page
BioinformaticsHome page
P. Flaherty, G. Giaever, J. Kumm, M. I. Jordan, and A. P. Arkin
A latent variable model for chemogenomic profiling
Bioinformatics, August 1, 2005; 21(15): 3286 - 3293.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. G. Belinsky, P. A. Dawson, I. Shchaveleva, L. J. Bain, R. Wang, V. Ling, Z.-S. Chen, A. Grinberg, H. Westphal, A. Klein-Szanto, et al.
Analysis of the In Vivo Functions of Mrp3
Mol. Pharmacol., July 1, 2005; 68(1): 160 - 168.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Wielinga, J. H. Hooijberg, S. Gunnarsdottir, I. Kathmann, G. Reid, N. Zelcer, K. van der Born, M. de Haas, I. van der Heijden, G. Kaspers, et al.
The Human Multidrug Resistance Protein MRP5 Transports Folates and Can Mediate Cellular Resistance against Antifolates
Cancer Res., May 15, 2005; 65(10): 4425 - 4430.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
J Wolf, T Stranzl, M Filipits, G Pohl, R Pirker, B Leeb, and J S Smolen
Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis
Ann Rheum Dis, April 1, 2005; 64(4): 564 - 568.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Filipits, G. Pohl, M. Rudas, O. Dietze, S. Lax, R. Grill, R. Pirker, C. C. Zielinski, H. Hausmaninger, E. Kubista, et al.
Clinical Role of Multidrug Resistance Protein 1 Expression in Chemotherapy Resistance in Early-Stage Breast Cancer: The Austrian Breast and Colorectal Cancer Study Group
J. Clin. Oncol., February 20, 2005; 23(6): 1161 - 1168.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Liu, Y. Ge, D. C. Cabelof, A. Aboukameel, A. R. Heydari, R. Mohammad, and L. H. Matherly
Structure and Regulation of the Murine Reduced Folate Carrier Gene: IDENTIFICATION OF FOUR NONCODING EXONS AND PROMOTERS AND REGULATION BY DIETARY FOLATES
J. Biol. Chem., February 18, 2005; 280(7): 5588 - 5597.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Z.-S. Chen, Y. Guo, M. G. Belinsky, E. Kotova, and G. D. Kruh
Transport of Bile Acids, Sulfated Steroids, Estradiol 17-{beta}-D-Glucuronide, and Leukotriene C4 by Human Multidrug Resistance Protein 8 (ABCC11)
Mol. Pharmacol., February 1, 2005; 67(2): 545 - 557.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
T. Shoji, H. Suzuki, H. Kusuhara, Y. Watanabe, S. Sakamoto, and Y. Sugiyama
ATP-dependent transport of organic anions into isolated basolateral membrane vesicles from rat intestine
Am J Physiol Gastrointest Liver Physiol, October 1, 2004; 287(4): G749 - G756.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Breedveld, N. Zelcer, D. Pluim, O. Sonmezer, M. M. Tibben, J. H. Beijnen, A. H. Schinkel, O. van Tellingen, P. Borst, and J. H. M. Schellens
Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions
Cancer Res., August 15, 2004; 64(16): 5804 - 5811.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Ifergan, A. Shafran, G. Jansen, J. H. Hooijberg, G. L. Scheffer, and Y. G. Assaraf
Folate Deprivation Results in the Loss of Breast Cancer Resistance Protein (BCRP/ABCG2) Expression: A ROLE FOR BCRP IN CELLULAR FOLATE HOMEOSTASIS
J. Biol. Chem., June 11, 2004; 279(24): 25527 - 25534.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. L. Volk and E. Schneider
Wild-Type Breast Cancer Resistance Protein (BCRP/ABCG2) is a Methotrexate Polyglutamate Transporter
Cancer Res., September 1, 2003; 63(17): 5538 - 5543.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Stark, L. Rothem, G. Jansen, G. L. Scheffer, I. D. Goldman, and Y. G. Assaraf
Antifolate Resistance Associated with Loss of MRP1 Expression and Function in Chinese Hamster Ovary Cells with Markedly Impaired Export of Folate and Cholate
Mol. Pharmacol., August 1, 2003; 64(2): 220 - 227.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z.-S. Chen, R. W. Robey, M. G. Belinsky, I. Shchaveleva, X.-Q. Ren, Y. Sugimoto, D. D. Ross, S. E. Bates, and G. D. Kruh
Transport of Methotrexate, Methotrexate Polyglutamates, and 17{beta}-Estradiol 17-({beta}-D-glucuronide) by ABCG2: Effects of Acquired Mutations at R482 on Methotrexate Transport
Cancer Res., July 15, 2003; 63(14): 4048 - 4054.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Zelcer, M. T. Huisman, G. Reid, P. Wielinga, P. Breedveld, A. Kuil, P. Knipscheer, J. H. M. Schellens, A. H. Schinkel, and P. Borst
Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP Binding Cassette C2)
J. Biol. Chem., June 20, 2003; 278(26): 23538 - 23544.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
S L Hider, C Morgan, E Bell, I N Bruce, P Ranganathan, and H L McLeod
Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with RA?
Ann Rheum Dis, June 1, 2003; 62(6): 591 - 591.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. G. Assaraf, L. Rothem, J. H. Hooijberg, M. Stark, I. Ifergan, I. Kathmann, B. A. C. Dijkmans, G. J. Peters, and G. Jansen
Loss of Multidrug Resistance Protein 1 Expression and Folate Efflux Activity Results in a Highly Concentrative Folate Transport in Human Leukemia Cells
J. Biol. Chem., February 21, 2003; 278(9): 6680 - 6686.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Z.-S. Chen, E. Hopper-Borge, M. G. Belinsky, I. Shchaveleva, E. Kotova, and G. D. Kruh
Characterization of the Transport Properties of Human Multidrug Resistance Protein 7 (MRP7, ABCC10)
Mol. Pharmacol., February 1, 2003; 63(2): 351 - 358.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
C. J. Oleschuk, R. G. Deeley, and S. P. C. Cole
Substitution of Trp1242 of TM17 alters substrate specificity of human multidrug resistance protein 3
Am J Physiol Gastrointest Liver Physiol, February 1, 2003; 284(2): G280 - G289.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T.-F. Fu, J. N. Scarsdale, G. Kazanina, V. Schirch, and H. T. Wright
Location of the Pteroylpolyglutamate-binding Site on Rabbit Cytosolic Serine Hydroxymethyltransferase
J. Biol. Chem., January 17, 2003; 278(4): 2645 - 2653.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Koike, C. J. Oleschuk, A. Haimeur, S. L. Olsen, R. G. Deeley, and S. P. C. Cole
Multiple Membrane-associated Tryptophan Residues Contribute to the Transport Activity and Substrate Specificity of the Human Multidrug Resistance Protein, MRP1
J. Biol. Chem., December 13, 2002; 277(51): 49495 - 49503.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Haimeur, R. G. Deeley, and S. P. C. Cole
Charged Amino Acids in the Sixth Transmembrane Helix of Multidrug Resistance Protein 1 (MRP1/ABCC1) Are Critical Determinants of Transport Activity
J. Biol. Chem., October 25, 2002; 277(44): 41326 - 41333.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. L. Volk, K. M. Farley, Y. Wu, F. Li, R. W. Robey, and E. Schneider
Overexpression of Wild-Type Breast Cancer Resistance Protein Mediates Methotrexate Resistance
Cancer Res., September 1, 2002; 62(17): 5035 - 5040.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z.-S. Chen, K. Lee, S. Walther, R. B. Raftogianis, M. Kuwano, H. Zeng, and G. D. Kruh
Analysis of Methotrexate and Folate Transport by Multidrug Resistance Protein 4 (ABCC4): MRP4 Is a Component of the Methotrexate Efflux System
Cancer Res., June 1, 2002; 62(11): 3144 - 3150.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.